A wet granulation line producing 250 mg chewable tablets for canine NSAIDs or ectoparasiticides requires a binder that yields a granule fraction above 45% retained on a 250 µm screen after 6 min of high-shear mixing. Sodium carboxymethylcellulose with a degree of substitution of 0.65–0.90 is dispersed in purified water at 2.0–4.0% w/w and added at a binder solution volume equivalent to 8–14% of dry powder mass in a high-shear granulator with an impeller tip speed of 5–8 m/s. The granulation endpoint is controlled by impeller power consumption and wet mass torque, not by fixed time alone; the power plateau after water addition indicates near-complete binder distribution. Wet granules are passed through a 1.5–2.0 mm conical mill, dried in a fluid bed at inlet air temperature 60–70°C to a loss on drying below 2.0%, and compressed on a rotary tablet press with precompression force 5–10 kN and main compression force 12–20 kN. In this configuration CMC-Na functions simultaneously as binder and disintegrant because partially hydrated particles swell upon contact with the aqueous dissolution medium. Tablets are tested according to USP <701> disintegration, with a maximum of 15 min in 0.1 N hydrochloric acid at 37°C for an uncoated chewable tablet, and USP <711> dissolution, with a Q value of 80% at 30 min for certain canine formulations. The CMC-Na content in the tablet core is limited to 6.0% w/w because higher fractions increase wetting time and reduce tensile strength; hardness values of 80–120 N and friability below 0.8% after 100 revolutions per USP <1216> are typical at binder levels below this limit. Hydration during solution preparation must be controlled: the dry polymer is added to the vortex of purified water at 15–25°C using a rotor-stator mixer, not directly into heated water, because localized heating above 45°C before full dispersion forms fish-eye agglomerates that persist through milling and create rough tablet surfaces. Steam-jacketed preparation tanks are maintained below this threshold until the solution is optically clear. The binder solution should be used within 24 h when preserved water is not part of the process; unpreserved solutions held longer at 20–25°C may develop microbial growth that alters esterase activity and final granule pH. Cleaning of the high-shear bowl after contact with acidic film-coating residues requires rinsing with purified water at 40–50°C to avoid gel formation in drain lines.

How Does Low-Viscosity CMC-Na Maintain Syringeability in Sterile Aqueous Suspensions for Intramuscular Depot Injection in Cattle?

Sterile aqueous suspensions for intramuscular or subcutaneous depot administration in livestock present a particle settling problem that is controlled by sodium carboxymethylcellulose at a final concentration of 0.5–1.2% w/v. The selected grade is a low-DS range of 0.50–0.70 with a 2% w/w solution viscosity of 20–80 mPa·s at 25°C measured by rotational viscometry according to ASTM D2196; this viscosity window allows passage through an 18G or 19G needle while limiting settling velocity of micronized active pharmaceutical ingredient with a D90 below 10 µm. Terminal sterilization of the vehicle must be evaluated in every batch because autoclaving at 121°C for 15 min can reduce apparent viscosity by 15–30% via hydrolytic chain scission if the pH drifts below 4.5 or above 8.0. The vehicle is therefore adjusted to pH 5.5–7.5 with dilute hydrochloric acid or sodium hydroxide before heat sterilization, and viscosity is re-qualified after sterilization by ASTM D2196 rather than relying on pre-sterilization values. Sterile filtration of high-molecular-weight CMC-Na through a 0.22 µm membrane is not operationally feasible for many commercial grades because the polymer rapidly plugs the membrane; aseptic compounding with gamma-irradiated CMC-Na or dry heat treatment is therefore used for heat-sensitive actives. Suspensions must pass USP <71> sterility testing and USP <85> bacterial endotoxin limits; the endotoxin limit is derived from the maximum administered dose and body weight of the target species. Monograph compliance for injectable-grade carboxymethylcellulose sodium requires control of chloride, free glycolate, and heavy metals, because free glycolate above 0.4% w/w shifts pH and alters suspension stability during long-term storage. In a wet ball mill or high-pressure homogenizer, the active is wetted with a CMC-Na solution containing 0.1% w/v polysorbate 80 at 15–25°C; high shear above 40°C causes local viscosity loss and changes particle size distribution. The finished product is filled into Type II glass vials under nitrogen overlay if the active is oxygen-sensitive; nitrogen overlay does not affect CMC-Na hydration. For suspensions with CMC-Na concentrations below 0.6% w/v, the flocculated network is weak and package inserts must instruct rolling rather than vigorous shaking to avoid foam entrapment. CMC-Na for parenteral use is incompatible with cationic antimicrobial preservatives such as benzalkonium chloride and chlorhexidine, and with high concentrations of multivalent cations such as calcium and aluminum; these combinations can form insoluble complexes or gels. Published data for gamma-irradiated low-DS veterinary parenteral grade viscosity shift at production scale is limited; each irradiation lot should be evaluated at 2% w/w solution viscosity before compounding.

Unlike wet granulation, low-dose capsule filling for companion animal anti-infectives or antiparasitic powders uses dry blending of carboxymethylcellulose sodium at 1.0–2.5% w/w to avoid moisture-induced hydrolysis of the active. In a V-blender or bin blender operating at 12–18 rpm for 15–20 min, powdered CMC-Na with a bulk density of 0.35–0.55 g/cm³ and a mean particle size of 75–150 µm is added after geometric preblending with directly compressible lactose and croscarmellose sodium. The blend is transferred to an automatic capsule filling machine with dosing disks selected by tapped bulk density according to USP <616>; powder flow through the dosator or tamping pin requires a Carr index below 25%. CMC-Na contributes to plug formation by plastic deformation under tamping pressure of 50–200 N, allowing the plug to retain shape during ejection into a hard gelatin capsule shell. Capsule disintegration is measured in 0.1 N hydrochloric acid with discs using USP <701>; formulations with CMC-Na alone at 1.5% w/w typically restrict disintegration to 8–15 min for size 0 capsules. If faster disintegration below 8 min is required, a portion of CMC-Na is replaced by crospovidone at 1.5–3.0% w/w, but the soluble CMC-Na fraction must not exceed 3.5% w/w because it forms a gel layer around the powder plug and slows release. Moisture in the dry blend is controlled below 3.0% loss on drying; the encapsulation suite is maintained at 35–50% RH because higher ambient RH above 60% causes CMC-Na to plasticize and stick to tamping pins. If CMC-Na powder has been stored at RH above 60%, it is pre-dried at 50°C for 2 h in a tray dryer before weighing. Cleaning validation after CMC-Na capsule runs uses a two-step wash with cold water to swell residual polymer, followed by a 45°C purified water rinse to dissolve the gel film from contact parts.

Medicated Premix Granulation Binder Levels, Dust Control, and Feed Redispersion for Swine and Poultry

Carboxymethylcellulose sodium grade selection for medicated premix granules intended for incorporation into swine and poultry feed at 0.1–1.0 kg per tonne is driven by dust reduction and dispersibility in final mash. A low-to-medium viscosity type with DS 0.70–0.90 and a 2% solution viscosity of 100–300 mPa·s at 25°C is dissolved in water at 3.0–5.0% w/w and sprayed at 30–60 g/min per kg of dry premix onto a fluid-bed top-spray granulator, with inlet air temperature 55–65°C and product temperature 30–40°C. The binder solution volume corresponds to 5–10% of dry powder mass; over-wetting above this range produces oversized granules and creates dead zones in the fluid bed. Granule size distribution after drying is maintained with a D50 of 250–500 µm, and fines below 75 µm are kept below 5% to pass dustiness testing according to DIN 55992-2 or an equivalent gravimetric Heubach Dustmeter method. The CMC-Na film on carrier particles such as ground corn cob, wheat middlings, or lactose reduces airborne active carryover and improves homogeneity measured as a coefficient of variation below 5% across ten thief samples from a ribbon blender. In feed, CMC-Na rehydrates within 3–5 min in gastric fluid at pH 2–5; granules disintegrate into primary particles without forming a stable gel that would impede active release, provided the premix contains less than 0.5% w/w of soluble calcium salts because calcium ions crosslink CMC-Na and slow dissolution. Equipment cleaning after CMC-Na-based premixes requires washing with ambient water before caustic cleaning; hot caustic solutions above 60°C degrade residual CMC-Na into glycolate derivatives that leave sticky films on dryer screens. Regulatory acceptance for food-producing animal premixes may reference GRAS status under 21 CFR 182.1745, but batch release must still meet the USP-NF monograph for carboxymethylcellulose sodium with respect to viscosity, degree of substitution, and loss on drying.

Viscosity Loss in Oral Suspension Vehicles Remains Below 10% at Neutral pH

Liquid oral dosage forms for poultry, swine, and companion animals often contain insoluble active pharmaceutical ingredients that settle within 24 h; CMC-Na functions as a suspending and viscosity-building agent at 0.25–1.0% w/v. The polymer is hydrated under high shear in purified water at 20–30°C for at least 60 min until the solution reaches an apparent viscosity of 50–200 mPa·s at 25°C and 30 rpm, measured according to ASTM D2196. Below 50 mPa·s, sedimentation velocity of dense API particles above 1.8 g/cm³ exceeds 1 cm/day in a 100 mL graduated cylinder, so label instructions for shaking before use become critical; above 200 mPa·s, the product drains slowly from automatic dosing pumps and may clog narrow drinking-line nipples in poultry houses. CMC-Na is anionic and must not be combined with cationic preservatives such as benzalkonium chloride or chlorhexidine because insoluble complexes form and reduce preservative activity. Sodium benzoate at 0.1% w/v and potassium sorbate at 0.1% w/v are compatible when the finished pH is 4.5–5.5; below pH 4.0, CMC-Na converts to the less soluble acid form and loses thickening efficiency. When the formulated oral vehicle is buffered at pH 6.0–7.0, viscosity loss over 6 months at 25°C is usually below 10%, whereas storage below pH 4.0 accelerates conversion to the acid form and greater loss. The preserved multi-dose product is challenged according to USP <51> antimicrobial effectiveness testing using the required bacterial and fungal strains; acceptance criteria for oral products are defined by that chapter. Sodium metabisulfite at 0.1% w/v as an antioxidant can reduce CMC-Na viscosity during storage at 40°C over 6 months through oxidative chain scission; stability indicating viscosity measurement at 25°C and 30 rpm is required when sulfite is present. CMC-Na solutions are shipped in high-density polyethylene containers with headspace below 5% of fill volume to reduce oxidative degradation; the product should not be frozen because freeze-thaw cycles cause polymer aggregation and irreversible viscosity loss.

In intramammary infusion preparations for lactating dairy cattle, the vehicle must remain in the mammary gland after administration through a 2.7 mm teat cannula while still allowing complete emptying from a 10 mL polyethylene syringe. CMC-Na at 1.0–2.0% w/v in an aqueous vehicle provides a shear-thinning gel with a viscosity of 2000–5000 mPa·s at 0.1 s⁻¹ and 200–600 mPa·s at 10 s⁻¹ when measured with a cone-and-plate rheometer at 25°C. The shear-thinning behavior is essential because the formulation resists leakage from the teat canal at rest but flows under manual syringe pressure. The gel is prepared by hydrating a medium-viscosity grade with a 2% solution viscosity of 300–800 mPa·s in water-for-injection containing 0.1% w/v methylparaben and 0.05% w/v propylparaben; pH is adjusted to 6.0–7.0 to avoid irritation of the mammary epithelium. Active pharmaceutical ingredients such as beta-lactams or aminoglycosides are suspended after wetting with a small quantity of polysorbate 80; particle size of the suspended drug is controlled below 25 µm to prevent cannula plugging. Terminal sterilization by autoclaving at 121°C for 15 min is applied to the vehicle when the active is heat stable; viscosity loss after autoclaving is typically less than 10% if the pH is maintained at 6.0–7.0 and oxygen is purged with nitrogen. If the active cannot be autoclaved, the CMC-Na gel is sterilized separately and the active is added aseptically. The finished product must pass USP <71> sterility testing and a syringeability test using a texture analyzer fitted with a 50 N load cell; the maximum expulsion force at 25°C should not exceed 25 N for a single-hand field application. Storage at 2–8°C can increase viscosity by 20–40%; the product is therefore brought to 20–25°C before administration. Published data for bovine intramammary gel retention times at production scale is limited; a formulation with 1.5% w/v CMC-Na and a viscosity plateau at 0.1 s⁻¹ above 3000 mPa·s is generally considered a starting point for retention studies.